Novartis AG$154.50ABBV · NYSE
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B | $45.80B | $33.27B | $32.75B |
| Cost of Revenue | $18.20B | $16.90B | $20.41B | $17.41B | $17.45B | $15.39B | $7.44B | $7.72B |
| Selling, General & Administrative | $14.01B | $14.75B | $12.87B | $15.26B | $12.35B | $11.30B | $6.94B | $7.40B |
| Operating Expenses | $46.09B | $47.20B | $41.56B | $39.94B | $38.27B | $34.44B | $20.28B | $26.37B |
| Operating Income | $15.07B | $9.14B | $12.76B | $18.12B | $17.92B | $11.36B | $12.98B | $6.38B |
| Interest Expense | $2.89B | $2.81B | $2.22B | $2.23B | $2.42B | $2.45B | $1.78B | $1.35B |
| Other Income / (Expense) | -$5.79B | -$3.24B | -$4.68B | -$2.45B | -$2.50B | -$5.61B | -$3.01B | -$18.00M |
| Income Before Taxes | $6.60B | $3.72B | $6.25B | $13.48B | $12.99B | $3.40B | $8.43B | $5.20B |
| Provision for Income Taxes | $2.36B | -$570.00M | $1.38B | $1.63B | $1.44B | -$1.22B | $544.00M | -$490.00M |
| Net Income | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B | $4.62B | $7.88B | $5.69B |
| Basic EPS | $2.37 | $2.40 | $2.73 | $6.65 | $6.48 | $2.73 | $5.30 | $3.67 |
| Diluted EPS | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 | $2.72 | $5.28 | $3.66 |
| Basic Shares Outstanding | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.67B | 1.48B | 1.54B |
| Diluted Shares Outstanding | 1.77B | 1.77B | 1.77B | 1.78B | 1.78B | 1.67B | 1.48B | 1.55B |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Dec 2026 | $14.06 | $13.90 | $14.54 | 9 | ↑0 ↓9 |
| Dec 2027 | $16.21 | $15.20 | $17.38 | 10 | ↑4 ↓2 |
| Dec 2028 | $17.84 | $16.49 | $19.61 | 5 | ↑3 ↓1 |
| Dec 2029 | $18.06 | $17.57 | $18.81 | 3 | ↑2 ↓0 |
